MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
نویسندگان
چکیده
منابع مشابه
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.
A hypoxic microenvironment induces resistance to alkylating agents by activating targets in the mammalian target of rapamycin (mTOR) pathway. The molecular mechanisms involved in this mTOR-mediated hypoxia-induced chemoresistance, however, are unclear. Here we identify the mTOR target N-myc downstream regulated gene 1 (NDRG1) as a key determinant of resistance toward alkylating chemotherapy, dr...
متن کاملDNA repair and resistance of gliomas to chemotherapy and radiotherapy.
The importance of DNA repair as a resistance mechanism in gliomas, the most aggressive form of brain tumor, is a clinically relevant topic. Recent studies show that not all cells are equally malignant in gliomas. Certain subpopulations are particularly prone to drive tumor progression and resist chemo- and radiotherapy. Those cells have been variably named cancer stem cells or cancer-initiating...
متن کاملGenomic Abnormalities in Gliomas
In general, studies reveal that cancer arises through genetic and epigenetic alterations that affect specific genes within a given cell type. These changes involve a gain of function when the alterations involve oncogenes, a loss of function when the target genes are tumor suppressor genes. Thus, both genetic and epigenetic changes promote the instability of cellular homeostasis (Bello & Rey, 2...
متن کاملBIOLOGICAL SCIENCES: Medical Sciences The mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
A hypoxic microenvironment induces resistance to alkylating agents by activating targets in the mammalian target of rapamycin (mTOR) pathway. The molecular mechanisms involved in this mTOR-mediated hypoxia-induced chemoresistance, however, are unclear. Here we identify the mTOR target N-myc downstream regulated gene 1 (NDRG1) as a key determinant of resistance toward alkylating chemotherapy, dr...
متن کاملLarge genomic rearrangements in MECP2.
In 1999, mutations in the X-linked gene methyl-CpG-binding protein 2 (MECP2) were first reported in patients with Rett syndrome (RTT). The MECP2 gene is located at Xq28 and consists of 4 exons. About 80-90 % of the classic RTT patients harbor mutations in the coding region of MECP2, while the molecular cause is unknown in the remaining 10-20%. Several groups have searched for large rearrangemen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Communications
سال: 2020
ISSN: 2041-1723
DOI: 10.1038/s41467-020-17717-0